

Bioresorbable vascular scaffold deemed noninferior

October 13 2015



(HealthDay)—For patients with noncomplex obstructive coronary artery disease, treatment with an everolimus-eluting bioresorbable vascular scaffold is noninferior to treatment with an everolimus-eluting cobalt-chromium stent, according to a study published online Oct. 12 in the *New England Journal of Medicine* to coincide with the Transcatheter Cardiovascular Therapeutics meeting, held from Oct. 11 to 15 in San Francisco.

Stephen G. Ellis, M.D., from the Cleveland Clinic, and colleagues conducted a multicenter, randomized trial involving patients with stable or unstable angina who were randomized in a 2-to-1 ratio to receive an everolimus-eluting bioresorbable vascular scaffold (Absorb; 1,322 patients) or an everolimus-eluting cobalt-chromium stent (Xience; 686 patients). The primary end point was target-lesion failure (cardiac death,

target-vessel myocardial infarction, or ischemia-driven target-lesion revascularization) at one year.

The researchers found that 7.8 and 6.1 percent of patients in the Absorb and Xience groups, respectively, had target-lesion failure at one-year (difference, 1.7 percentage points; $P = 0.007$ for noninferiority and $P = 0.16$ for superiority). No significant between-group differences were seen in the rates of cardiac death, target-vessel myocardial infarction, or ischemia-driven target-lesion revascularization. Device thrombosis occurred in 1.5 and 0.7 percent of [patients](#) in the Absorb and Xience groups, respectively, within one year ($P = 0.13$)

"Treatment of noncomplex obstructive [coronary artery disease](#) with an everolimus-eluting bioresorbable vascular scaffold, as compared with an everolimus-eluting cobalt-chromium stent, was within the prespecified margin for noninferiority with respect to target-lesion [failure](#) at one year," the authors write.

The study was funded by Abbot Vascular.

More information: [Abstract](#)
[Full Text \(subscription or payment may be required\)](#)
[More Information](#)

Copyright © 2015 [HealthDay](#). All rights reserved.

Citation: Bioresorbable vascular scaffold deemed noninferior (2015, October 13) retrieved 4 May 2024 from <https://medicalxpress.com/news/2015-10-bioresorbable-vascular-scaffold-deemed-noninferior.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
